NCT00367484View on ClinicalTrials.gov

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL

Enrollment

460

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

BIOLOGICAL

Rebif® (clone 484-39)

s.c. administered Rebif®

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00367484 - Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis | Biotech Hunter | Biotech Hunter